NCT07194187尚未招募不适用
High Intensity Focused Ultrasound (HIFU) Ablation for Treatment of Prostate Tissue in Bladder Outlet Obstruction
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 17
- 试验地点
- 2
- 主要终点
- Change in The International Prostate Symptom Score (I-PSS)
研究概览
简要总结
Objectives: To assess the efficacy of HIFU therapy for benign prostatic tissue ablation in patients with lower urinary tract symptoms (LUTS) due to bladder outlet obstruction (BOO) that caused by Benign prostatic hyperplasia (BPH).
The primary objective of the study is to determine the efficacy of HIFU therapy by assessing the changes in IPSS score in 6-month post HIFU procedure for BPH with compared to baseline.
The secondary objectives of this study are as follow:
- To assess any adverse events related to the procedure or device.
- To assess the operation related characteristics including: total operation time and ablation time required in HIFU procedure for BPH, total catheterization time after the HIFU procedure for BPH, and categorical ablation zone
- To assess the patient's post operative pain level at different post op time points.
- To assess the urinary flow and symptoms improvement by studying the changes in IPSS, Qmax, and PVR at different post op time points compared to the baseline.
- To assess the effectiveness of HIFU by studying the changes in PSA levels, types of medication for BPH or any urologic condition, proportion of patients who are taking BPH medication, prostate volume, and prostate calcification level and the reoperation rate within 12-month post-op.
- To assess changes in patients' sexual function at different post op time points.
The hypothesis is that a HIFU ablation is a safe and effective treatment for patients with LUTS due to BOO from BPH.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 45 Years 至 80 Years（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Males aged 45 - 80 diagnosed with LUTS due to BOO from BPH.
- •Prostate size > 30cc and < 80cc as measured by transrectal ultrasound (TRUS) or MRI within 1 year prior to treatment.
- •A documented history of refusal to take medical therapy, inadequate or failed response to medical therapy, or contraindications to medical therapy.
- •Initial baseline International Prostate Symptom Score (IPSS) greater than or equal to 12 which denotes moderate to severe symptoms.
- •Baseline peak urinary flow rate (Qmax) of less than 15 mL/s1
- •Baseline serum creatinine < 2 mg/dL within 30 days prior to surgery
- •Mental capacity, willingness, and ability to sign a study specific informed consent form
排除标准
- •BMI > 42
- •Patients with an obstructing prostatic median lobe as measured by baseline preliminary imaging and/or confirmed on cystoscopy examination.
- •Patients with latex allergies which would permit latex catheterization perioperatively as silicone catheterization is not recommended during HIFU treatment.
- •Patients with extensive calcification in the treatment area of the prostate as measured by preoperative imaging with TRUS or MRI and as evaluated by hospital radiology or the principal investigator. Extensive calcification is defined as where the calcification in posterior peripheral zone, which may interfere with experimental treatment procedure, and it is determined by hospital radiologist and further assessed by the PI.
- •Patient unable to stop anticoagulants, antiplatelet agents, or NSAIDS (including aspirin > 100mg) prior to treatment which is standard of care.
- •Patients using immunosuppressants including corticosteroids (except inhalants) who are unable to withhold medications prior to treatment which is standard of care.
- •Known and documented coagulopathy or platelet disorder
- •Contraindication to both general and spinal anesthesia which are standard of care.
- •Severe illness that would prevent complete study participation.
- •History of active or prior treatments for current/suspected PCa.
- •Diagnosis of polyneuropathy
- •Bladder calculi or bladder diverticulum (pouch size > 20% of full bladder size)
- •Active infection, including urinary tract infection or prostatitis.
- •Evidence of hydronephrosis on imaging.
- •Pre-op urinary catheter uses daily.
- •Previous urinary tract surgeries such as, but not limited to prior surgery for LUTS, urinary diversion, artificial urinary sphincter, or penile prosthesis.
- •Diagnosis of clinically significant urethral stricture, meatal stenosis, severe phimosis, or bladder neck contracture
- •Known damage to the external urinary sphincter.
- •Open heart surgery or cardiac arrest < 180 days prior to the date of informed consent
- •Known illicit substance abuse.
- •Use of anticholinergics (specifically for bladder problems). Use of general anticholinergics is allowed if they do not have documented adverse urinary side effects.
- •Dementia or psychiatric conditions which prevent them from completing the required follow up.
- •Prior pelvic radiotherapy
- •Participation in another ongoing investigational study that could affect responses.
- •Unwillingness to accept a transfusion should it be required.
- •No members of vulnerable populations will be included in our study.
- •History or current diagnosis of chronic prostatitis.
- •Diagnosis or prior treatment for chronic pelvic pain syndrome.
研究组 & 干预措施
Participants with benign prostatic hyperplasia
Experimental
HIFU therapy for benign prostatic tissue ablation in patients with lower urinary tract symptoms (LUTS) due to bladder outlet obstruction
干预措施: High Intensity Focused Ultrasound (Device)
结局指标
主要结局
Change in The International Prostate Symptom Score (I-PSS)
时间窗: baseline and 6 months post-treatment
The International Prostate Symptom Score (I-PSS) is designed to assess severity of symptoms in benign prostatic hypertrophy. It is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life. Each question concerning urinary symptoms allows the patient to choose one out of six answers indicating increasing severity of the particular symptom. The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 with higher score indicating more symptomatic. It classifies patients' symptomatology as follows: Mild (symptom score ≤ 7), Moderate (score 8-19), and Severe (score 20-35).
次要结局
- Frequency and proportions of adverse events and all cause hospitalization(within the first 30 days after the HIFU intervention)
- Operation time(approximately 45-120 minutes)
- Ablation time(average 15-45 minutes)
- Catheterization times(1 week post-procedure, or until the patient passes the trial of void)
- Categorical Ablation Zones (Peripheral, Transitional, or Central Prostate Zones)(During procedure)
- Changes in maximum flow rate (Qmax)(Baseline, 1-, 3-, 6-, 12- months post-treatment)
- Male-Genitourinary Pain Index (M-GUPI) pain questionnaire(at discharge after HIFU procedure (expected time: Post-op Day 1), 1-week and 1-month post-op)
- Changes in IPSS scores(Baseline, 1-, 3-, 12- months post-treatment)
- Changes in Post-Void Residual (PVR)(Baseline, 1-, 3-, 6-, 12- months post-treatment)
- Changes in the type of BPH medications(Baseline, 1 week, 1-, 3-, 6-, and 12- month post-treatment)
- Change in Prostate Specific Antigen (PSA) level.(Baseline, 6-, and 12- month post-treatment)
- Change in Prostate measurement(Baseline, 6-, and 12- month post-treatment)
- Number of BPH procedures(12- month post-treatment)
- Change in the International Index of Erectile Function (IIEF) questionnaire(Baseline, 3- and 6- months post treatment)
- Change in the Male Sexual Health Questionnaire- Ejaculatory Dysfunction (MSHQ-EjD)(Baseline, 3- and 6- months post treatment)
研究者
Michael Palese
Professor, Site Chair Department of Urology
Icahn School of Medicine at Mount Sinai
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Assessment of HIFU-induced Prostate Necrosis With Shear-wave Ultrasound ElastographyProstate CancerNCT01729442Hospices Civils de Lyon30
招募中
不适用
High Intensity Focused Ultrasound Treatment of Breast Tumors. BRIFU StudyBreast Cancer FemaleNCT03342625Institut Bergonié15
撤回
不适用
Investigational Study For the Treatment of Localized (T1c/T2a) Prostate Cancer With High Intensity Focused Ultrasound (HIFU) Using the Sonablate 500 (SB-500) System in CanadaProstate CancerNCT00537849SonaCare Medical
进行中（未招募）
不适用
HIFU for Treatment of Non-nodular and Recurrent BCCCarcinoma, Basal CellNCT05133427Joergen Serup40
Unknown
2 期
High-Intensity Focused Ultrasound Focal Ablation in Treating Patients With Progressive Prostate CancerProstate CancerSexual DysfunctionNCT00988130University College London Hospitals26